Skip to main content
OpenTrials
Completed

NCT Number: NCT02553018

Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe

The primary objective of the study is to compare, in patients treated with methotrexate injection for rheumatoid arthritis, the compliance and the health assessment questionnaire evolution for the administration by auto-injector versus administration by conventional subcutaneous injection, after 6 months of treatment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

SARAUX, Brest, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patient (18 years or over) of either sex.
  • With established rheumatoid arthritis diagnosis
  • Treated for rheumatoid arthritis by methotrexate (oral or by injection) since at least 3 months regardless of the prior or combined disease modifying treatment, except biotherapies and justifying injection of methotrexate. For the patient treated by oral methotrexate, the switch decided by the rheumatologist is made for either safety, compliance or efficacy issues.
  • Agreeing to participate in the study and having dated and signed the informed consent form.

Exclusion criteria

  • Patients fulfilling one or more of the following exclusion criteria will not be included in the study:
  • Inability of patient to use an auto-injector.
  • Treated with biotherapies.
  • Pregnant or breast-feeding patients
  • Male and female patients with reproductive potential who are not willing to use effective method of contraception (oral contraceptives, intrauterine device, condoms) during study and at least 1 month after the end of the study.
  • Patients with :
  • hypersensitivity to methotrexate or to any of the excipients,
  • severe hepatic impairment,
  • alcohol abuse,
  • severe renal impairment,
  • pre-existing blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia or significant anaemia,
  • Immunodeficiency,
  • serious, acute or chronic infections such as tuberculosis and HIV,
  • stomatitis, ulcers of the oral cavity and known active gastrointestinal ulcer disease,
  • concurrent vaccination with live vaccines.
  • Association with probenecid, trimethoprim, phenylbutazone.
  • Any other known medical or surgical history, disorder or disease judged by the investigator to be incompatible with the study (such as acute or chronic severe organic disease: hepatic, endocrine, neoplasia, haematological, infectious diseases, severe psychiatric illness, relevant cardiovascular abnormalities, etc…),
  • Inability of patient to understand the study procedures and thus inability to give informed consent.
  • Participation in another clinical study, at the same time as the present study, or during the month following the end of the previous study
  • Ward of court.
  • Patient not covered by the Social Security.

Treatment and study plan

methotrexate

Drug

Other names: Auto-injector of methotrexate, METOJECT

Primary outcomes

  1. Co-primary criteria: observance and health assessment questionnaire

    Time frame: 6 months

    the health assessment questionnaire is completed by the patient at inclusion visit and at the 6 months visit. Compliance with methotrexate treatment will be assessed by the investigator at each visit

Secondary outcomes

  1. quality of life

    Time frame: 6 months

    Patient's quality of life will be assessed using a validated questionnaire. completed by the patient at inclusion and 6 months visits. Change from baseline in questionnaire score will be described.

  2. acceptability

    Time frame: up to 1 year

    The product acceptability will be evaluated by the patient using a specific questionnaire based on several questions related to the patient' opinion, satisfaction and willingness to adopt the product.

  3. preference

    Time frame: 6 months

    Preference will be assessed only for patients receiving auto-injector and pre-filled syringe of methotrexate

  4. Economic

    Time frame: 6 months

    Information on the consumed resources for methotrexate administration will be assessed at 6 months. This information will be further incorporated in a budget impact for the French Sickness Fund

Sponsors and collaborators

Lead sponsor

Nordic Pharma SAS

Industry

Registry information

Official study title

A National, Randomized, Open-label Study Comparing Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated With Methotrexate Administered by Auto-injector Versus Administration by Conventional Subcutaneous Injection.

Acronym: Self-i

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Sep 17, 2015
Registry last updated
Oct 6, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.